RASopathies: From germline mutations to somatic and multigenic diseases

Area of Science:

• Molecular Biology
• Genetics
• Oncology

Background:

• The RAS-RAF-MEK-ERK signaling pathway regulates crucial cellular functions like proliferation, differentiation, and apoptosis.
• Mutations in this pathway are frequently observed in various cancers.
• Germline mutations in this pathway are associated with developmental disorders known as RASopathies.

Purpose of the Study:

• To review the spectrum of diseases caused by germline and somatic mutations in the RAS-RAF-MEK-ERK pathway.
• To elucidate the mechanisms by which gain-of-function mutations in this pathway lead to diverse clinical phenotypes.
• To highlight the shared mutational basis of seemingly distinct rare disorders.

Main Methods:

• Literature review of studies on RASopathies and RAS-associated rare somatic disorders.
• Analysis of genetic data linking mutations in the RAS-RAF-MEK-ERK pathway to specific diseases.
• Synthesis of information on the functional consequences of gain-of-function mutations.

Main Results:

• Gain-of-function mutations in the RAS-RAF-MEK-ERK pathway are implicated in both developmental disorders (RASopathies) and rare somatic conditions.
• The same mutations can manifest as different diseases depending on whether they are inherited (germline) or acquired (somatic).
• RAS-associated leukoproliferative diseases and histiocytosis are examples of rare somatic RASopathies linked to this pathway.

Conclusions:

• The RAS-RAF-MEK-ERK pathway is a critical determinant of cellular behavior, and its dysregulation through gain-of-function mutations underlies a range of human diseases.
• Understanding the molecular basis of these mutations provides insights into disease pathogenesis and potential therapeutic strategies.
• This review underscores the importance of targeting this pathway for conditions ranging from developmental abnormalities to rare cancers.